{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:45:40Z","timestamp":1794329140067,"version":"4.9.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["J Addict Med"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We aimed to determine medications\u2019 comparative efficacy and safety for adults with alcohol use disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched eleven electronic data sources for randomized clinical trials with at least 4 weeks of treatment reporting on alcohol consumption (total abstinence and reduced heavy drinking), dropouts, and dropouts due to adverse events. We conducted network meta-analyses using random-effects, frequentist models, and calculated summary rate ratios (RRs) with 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 156 trials (N = 27,334). Nefazodone (RR = 2.11; 95% CI, 1.42\u20133.13), aripiprazole (RR = 1.97; 95% CI, 1.36\u20132.88), carbamazepine (RR = 1.85; 95% CI, 1.03\u20133.32), and nalmefene (RR = 1.17; 95% CI, 1.01\u20131.35) were associated with the most dropouts. Baclofen (RR = 0.83; 95% CI, 0.70\u20130.97) and pregabalin (RR = 0.63; 95% CI, 0.43\u20130.94) caused fewer dropouts than placebo. Nalmefene (RR = 3.26; 95% CI, 2.34\u20134.55), fluvoxamine (RR = 3.08; 95% CI, 1.59\u20135.94), and topiramate (RR=2.18; 95% CI, 1.36\u20133.51) caused more dropouts from adverse events over placebo. Gamma-hydroxy-butyrate (RR = 1.90; 95% CI, 1.03\u20133.53), baclofen (RR = 1.80; 95% CI, 1.39\u20132.34), disulfiram (RR = 1.71; 95% CI, 1.39\u20132.10), gabapentin (RR = 1.66; 95% CI, 1.04\u20132.67), acamprosate (RR = 1.33; 95% CI, 1.15\u20131.54), and oral naltrexone (RR = 1.15; 95% CI, 1.01\u20131.32) improved total abstinence over placebo (Fig. 3C). For reduced heavy drinking, disulfiram (RR = 0.19; 95% CI, 0.10\u20130.35), baclofen (RR = 0.72; 95% CI, 0.57\u20130.91), acamprosate (RR = 0.78; 95% CI, 0.70\u20130.86), and oral naltrexone (RR = 0.81; 95% CI, 0.73\u20130.90) were efficacious against placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The current meta-analyses provide evidence that several medications for AUDs are effective and safe and encourage the expanded use of these medications in the clinical setting. Our review found that acamprosate (2\u20133 g\/d), disulfiram (250\u2013500 mg\/d), baclofen (30 mg\/d), and oral naltrexone (50 mg\/d) had the best evidence for improving abstinence and heavy drinking for patients with AUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO<\/jats:title>\n                    <jats:p>CRD42020208946.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/adm.0000000000000992","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T18:00:36Z","timestamp":1654192836000},"page":"630-638","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":68,"title":["Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis"],"prefix":"10.1097","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3490-314X","authenticated-orcid":false,"given":"Anees","family":"Bahji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paxton","family":"Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon","family":"Danilewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Crockford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Devoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nady","family":"el-Guebaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Saitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"12","key":"bib1-20250526","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S2215-0366(18)30337-7","article-title":"The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"5","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"bib3-20250526","first-page":"CD008544","article-title":"Anticonvulsants for alcohol dependence","volume":"13","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"bib4-20250526","first-page":"CD001867","article-title":"Opioid antagonists for alcohol dependence","volume":"8","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"bib5-20250526","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/add.14655","article-title":"A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder","volume":"114","year":"2019","journal-title":"Addiction"},{"issue":"1","key":"bib6-20250526","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1176\/appi.ajp.2017.1750101","article-title":"The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder","volume":"175","year":"2018","journal-title":"Am J Psychiatry"},{"issue":"2","key":"bib7-20250526","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/add.13974","article-title":"Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate","volume":"113","year":"2018","journal-title":"Addiction"},{"issue":"11","key":"bib8-20250526","first-page":"CD012557","volume":"11","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"bib9-20250526","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2018.11406","article-title":"Diagnosis and pharmacotherapy of alcohol use disorder: a review","volume":"320","year":"2018","journal-title":"JAMA"},{"issue":"7","key":"bib10-20250526","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/add.13324","article-title":"Gabapentin misuse, abuse, and diversion: a systematic review","volume":"111","year":"2016","journal-title":"Addiction"},{"issue":"8","key":"bib11-20250526","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1177\/1060028015585849","article-title":"The role of gabapentin in the management of alcohol withdrawal and dependence","volume":"49","year":"2015","journal-title":"Ann Pharmacother"},{"key":"bib12-20250526","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings a systematic review and meta-analysis","volume":"311","year":"2014","journal-title":"JAMA"},{"issue":"2","key":"bib13-20250526","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","year":"2012","journal-title":"Res Synth Methods"},{"issue":"11","key":"bib14-20250526","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","year":"2015","journal-title":"Ann Intern Med"},{"issue":"7829","key":"bib16-20250526","first-page":"d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","year":"2011","journal-title":"BMJ"},{"issue":"58","key":"bib18-20250526","first-page":"58","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","year":"2015","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"bib19-20250526","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","article-title":"Network meta-analysis: an introduction for clinicians","volume":"12","year":"2017","journal-title":"Intern Emerg Med"},{"issue":"7414","key":"bib20-20250526","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","year":"2003","journal-title":"BMJ"},{"issue":"2","key":"bib21-20250526","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","year":"2010","journal-title":"Res Synth Methods"},{"issue":"7650","key":"bib22-20250526","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","year":"2008","journal-title":"BMJ"},{"issue":"7109","key":"bib23-20250526","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","year":"1997","journal-title":"BMJ"},{"issue":"2\u20133","key":"bib24-20250526","first-page":"167","article-title":"Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients","volume":"178","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"bib25-20250526","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/JCP.0b013e3181ac5213","article-title":"Targeted naltrexone for problem drinkers","volume":"29","year":"2009","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"bib27-20250526","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jsat.2014.03.007","article-title":"Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies","volume":"47","year":"2014","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"bib28-20250526","doi-asserted-by":"crossref","first-page":"e87366","DOI":"10.1371\/journal.pone.0087366","article-title":"Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis","volume":"9","year":"2014","journal-title":"PLoS ONE"},{"issue":"3","key":"bib29-20250526","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/01.jcp.0000222512.25649.08","article-title":"The status of disulfiram: a half of a century later","volume":"26","year":"2006","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"bib30-20250526","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/alcalc\/agm136","article-title":"A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence","volume":"43","year":"2008","journal-title":"Alcohol Alcohol"},{"issue":"1","key":"bib31-20250526","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/acer.13917","article-title":"Gabapentin enacarbil extended release for alcohol use disorder: a randomized, double-blind, placebo-controlled, multisite trial assessing efficacy and safety","volume":"43","year":"2019","journal-title":"Alcohol Clin Exp Res"},{"issue":"3","key":"bib32-20250526","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/acps.12905","article-title":"Baclofen for alcohol use disorder: a systematic meta-analysis","volume":"138","year":"2018","journal-title":"Acta Psychiatr Scand"},{"issue":"5","key":"bib33-20250526","first-page":"e277","article-title":"First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario","volume":"63","year":"2017","journal-title":"Can Fam Physician Med Fam Can"},{"issue":"3","key":"bib34-20250526","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/alcalc\/agh045","article-title":"Pharmacotherapeutic trials in adolescent alcohol use disorders: opportunities and challenges","volume":"39","year":"2004","journal-title":"Alcohol Alcohol"},{"issue":"Suppl 4","key":"bib35-20250526","first-page":"S290","article-title":"A developmental perspective on alcohol and youths 16 to 20 years of age","volume":"121","year":"2008","journal-title":"Pediatrics"},{"issue":"6","key":"bib36-20250526","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/14659890802305861","article-title":"An open randomized trial comparing disulfiram and naltrexone in adolescents with alcohol dependence","volume":"13","year":"2008","journal-title":"J Subst Use"},{"issue":"5","key":"bib37-20250526","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3109\/14659891.2013.813084","article-title":"A comparative study using disulfiram and naltrexone in alcohol-dependent adolescents","volume":"19","year":"2014","journal-title":"J Subst Use"},{"issue":"2","key":"bib38-20250526","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/HRP.0000000000000070","article-title":"Alcohol use disorders in pregnancy","volume":"23","year":"2015","journal-title":"Harv Rev Psychiatry"},{"key":"bib39-20250526","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.2147\/PPA.S109641","article-title":"Patient-centered care interventions for the management of alcohol use disorders: a systematic review of randomized controlled trials","volume":"10","year":"2016","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"bib40-20250526","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/add.13974","article-title":"Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate: pharmacologically controlled drinking","volume":"113","year":"2018","journal-title":"Addiction"},{"issue":"2","key":"bib41-20250526","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0306-4603(96)00013-5","article-title":"Drinking goal selection in behavioral self-management treatment of chronic alcoholics","volume":"22","year":"1997","journal-title":"Addict Behav"},{"issue":"3","key":"bib42-20250526","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1037\/0893-164X.22.3.439","article-title":"Accounting for self-selected drinking goals in the assessment of treatment outcome","volume":"22","year":"2008","journal-title":"Psychol Addict Behav"},{"issue":"3","key":"bib43-20250526","first-page":"196","article-title":"Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness","volume":"13","year":"2015","journal-title":"JBI Evid Implement"}],"container-title":["Journal of Addiction Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ADM.0000000000000992","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T16:09:10Z","timestamp":1748275750000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ADM.0000000000000992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/adm.0000000000000992","relation":{},"ISSN":["1932-0620"],"issn-type":[{"value":"1932-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}